X4 Pharmaceuticals, Inc. Stock
X4 Pharmaceuticals, Inc. Stock
A loss of -2.620% shows a downward development for X4 Pharmaceuticals, Inc..
X4 Pharmaceuticals, Inc. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
Based on the current price of 1.02 € the target price of 3 € shows a potential of 193.54% for X4 Pharmaceuticals, Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for X4 Pharmaceuticals, Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of X4 Pharmaceuticals, Inc. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of X4 Pharmaceuticals, Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
X4 Pharmaceuticals, Inc. | -2.620% | 3.915% | 12.369% | -55.565% | 31.026% | - | - |
Ardelyx Inc. | -2.610% | -2.231% | -18.688% | 60.424% | 4.637% | -0.852% | - |
Evolus Inc | -2.750% | -4.386% | -6.034% | 46.309% | 20.442% | 20.442% | - |
Salarius Pharmaceuticals Inc. | - | 0.535% | -11.321% | -72.148% | -32.252% | -98.400% | -99.995% |
Comments
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $5.00 price target on the stock.
Show more
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target raised by analysts at HC Wainwright from $3.00 to $5.00. They now have a "buy" rating on the stock.
Show more
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Show more
Ratings data for XFOR provided by MarketBeat